Loading...
•
Dec 31, 2020
Denali Therapeutics Q4 2020 Earnings Report
Reported net income and increased collaboration revenue driven by the Biogen Collaboration Agreement.
Key Takeaways
Denali Therapeutics reported a net income of $244.9 million for Q4 2020, a significant increase compared to the net loss of $54.0 million in Q4 2019. The increase was primarily driven by $307.4 million of revenue recognized under the Biogen Collaboration Agreement. The company's cash, cash equivalents, and marketable securities were $1.5 billion as of December 31, 2020.
Reported positive 3-month data from Phase 1/2 study of DNL310 in patients with Hunter syndrome (MPS II).
Added five new Enzyme Transport Vehicle (ETV) programs for LSDs.
Completed Phase 1b study of DNL151 (BIIB122), supporting late-stage development.
Announced RIPK1 program updates, including Sanofi's submission of an investigational new drug (IND) application for DNL788 (SAR443820).
Denali Therapeutics
Denali Therapeutics
Forward Guidance
Denali anticipates an increase of approximately 20-25% in cash operating expenses compared to 2020.